Sign In
Buy ME
$0.606
+0 (+0%)
At Close: Sep 16, 2025
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
07:30am, Friday, 21'st Mar 2025
Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels Provides 23andMe+ Premium members with highly requested insigh
23andMe special committee again rejects CEO Wojcicki's take-private offer
06:16pm, Monday, 03'rd Mar 2025
23andMe's special committee of independent directors on Monday rejected CEO Anne Wojcicki's proposal to take the distressed genetic testing company private. Wojcicki submitted a proposal to the commit
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
04:35pm, Monday, 03'rd Mar 2025
SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt o
YourUpdateTV Speaks with Mathew Knowles and Ruth Tennen from 23andMe to Discuss Genetic Risk Factors for Cancer
11:01am, Monday, 24'th Feb 2025
Mathew Knowles, Male Breast Cancer Survivor and Father of Beyoncé and Solange, Teams with 23andMe to Discuss the Importance of Genetic Testing in Understanding Cancer Risk Factors Mathew Knowles, Mal
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
05:30pm, Friday, 21'st Feb 2025
23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the company private. They are offering to buy all outstanding shares in cash for $2.53 per share, or an equity valu
23andMe Launches New Genetic Report on Osteoporosis
07:30am, Friday, 31'st Jan 2025
Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants Provides 23andMe+ Premium members with insight into their likelih
23andMe is exploring strategic alternatives, looking to raise capital
06:59pm, Tuesday, 28'th Jan 2025
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.
23andMe Special Committee Announces Exploration of Strategic Alternatives
05:25pm, Tuesday, 28'th Jan 2025
SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) (“23andMe” or the “Company”), a leading human genetics
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
05:15pm, Tuesday, 28'th Jan 2025
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges
23andMe Reportedly Considers Selling Lemonaid Telehealth Unit
04:11pm, Sunday, 19'th Jan 2025
23andMe is reportedly considering the sale of Lemonaid Health, its telehealth operation. The consumer genetic testing kit company acquired Lemonaid in 2021 for $400 million and is now weighing a sale,
23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
02:13pm, Friday, 17'th Jan 2025
23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million.
23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their care 23andMe is helping collaborators better unders
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation
Thunder Bay, Ontario--(Newsfile Corp. - November 18, 2024) - Metals Creek Resources Corp. (TSXV: ME) (FSE: M1C1) (the "Company" or Metals Creek) further to its November 5, 2024 news release, the Co
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
06:56pm, Tuesday, 12'th Nov 2024
23andMe Holding Co. (NASDAQ:ME ) Q2 2025 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Katie Watson - Vice President, Communications Anne Wojcicki - Chief Executive Office
